Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Antimicrob Agents Chemother
2013 Nov 01;5711:5612-8. doi: 10.1128/AAC.01421-13.
Show Gene links
Show Anatomy links
Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro.
Moss DM
,
Liptrott NJ
,
Curley P
,
Siccardi M
,
Back DJ
,
Owen A
.
???displayArticle.abstract???
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor approved for treatment of HIV-1 infection in antiretroviral-naive adult patients. Potential interactions with drug transporters have not been fully investigated. Transport by and inhibition of drug transporters by rilpivirine were analyzed to further understand the mechanisms governing rilpivirine exposure and determine the potential for transporter-mediated drug-drug interactions. The ability of rilpivirine to inhibit or be transported by ABCB1 was determined using ABCB1-overexpressing CEMVBL100 cells and Caco-2 cell monolayers. The Xenopus laevis oocyte heterologous protein expression system was used to clarify if rilpivirine was either transported by or inhibited the function of influx transporters SLCO1A2, SLCO1B1, SLCO1B3, SLC22A2, SLC22A6, and SLC22A8. The ability of rilpivirine to inhibit or be transported by SLC22A1 was determined using SLC22A1-expressing KCL22 cells. Rilpivirine showed higher accumulation in SLC22A1-overexpressing KCL22 cells than control cells (27% increase, P = 0.03) and inhibited the functionality of SLC22A1 and SLC22A2 transport with 50% inhibitory concentrations (IC50s) of 28.5 μM and 5.13 μM, respectively. Inhibition of ABCB1-mediated digoxin transport was determined for rilpivirine, which inhibited digoxin transport in the B-to-A direction with an IC50 of 4.48 μM. The maximum rilpivirine concentration in plasma in patients following a standard 25-mg dosing regimen is around 0.43 μM, lower than that necessary to substantially inhibit ABCB1, SLC22A1, or SLC22A2 in vitro. However, these data indicate that SLC22A1 may contribute to variability in rilpivirine exposure and that interactions of rilpivirine with substrates of SLC22A1, SLC22A2, or ABCB1 may be possible.
Azijn,
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
2010, Pubmed
Azijn,
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
2010,
Pubmed
Bleasby,
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.
2006,
Pubmed
Cohen,
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
2011,
Pubmed
Cohen,
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
2013,
Pubmed
Crauwels,
Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
2013,
Pubmed
Elsby,
Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
2008,
Pubmed
Ernest,
Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney.
1997,
Pubmed
Giacomini,
Membrane transporters in drug development.
2010,
Pubmed
Giannoudis,
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
2008,
Pubmed
Hartkoorn,
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
2010,
Pubmed
,
Xenbase
Huang,
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
2008,
Pubmed
Janneh,
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.
2009,
Pubmed
Jung,
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.
2008,
Pubmed
Kis,
The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.
2010,
Pubmed
Lindell,
Variable expression of CYP and Pgp genes in the human small intestine.
2003,
Pubmed
Minematsu,
Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
2010,
Pubmed
Molina,
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
2011,
Pubmed
Moss,
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.
2011,
Pubmed
,
Xenbase
Reese,
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
2013,
Pubmed
Sharma,
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
2013,
Pubmed
Thiebaut,
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
1987,
Pubmed
Thomas,
Active transport of imatinib into and out of cells: implications for drug resistance.
2004,
Pubmed
Weiss,
Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
2013,
Pubmed
Zhang,
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
2000,
Pubmed
Zhang,
Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
2010,
Pubmed
van Lunzen,
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
2012,
Pubmed
